Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...

Women are disproportionately affected by HIV, making up nearly half of new infections globally and in India. Stigma, gender ...

Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...

Lenacapavir is an injectable medicine that only needs to be taken twice a year, making it easier to use than daily HIV pills.

China has announced a US$3.49 million (R60 million) partnership with South Africa to expand HIV prevention services among adolescents and young people, as ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Cryo-EM revealed HIV-1 integrase’s distinct structures as it shifts between its two roles of DNA integration and RNA-binding.